Oral Clodronate Therapy for Hypercalcemia Related to Extensive Subcutaneous Fat Necrosis in a Newborn

Hypercalcemia is occasionally found in newborns with subcutaneous fat necrosis and carries potential lifethreatening risk. Bisphosphonates have been recently introduced in the treatment of subcutaneous fat necrosis in newborns. We report a case of extensive subcutaneous fat necrosis in a female infant complicated with intractable hypercalcemia. Standard treatment for hypercalcemia was given, including saline hydration, a low calcium diet, furosemide, and glucocorticoid, but without response. Serum 1,25-dihydroxyvitamin D level was elevated at 126 pg/mL, 25-hydroxyvitamin D level was normal, and intact parathyroid hormone was suppressed at ＜ 1 pg/mL. Oral clodronate disodium, a second-generation bisphosphonate, was administered, and resulted in the normalization of serum calcium, urine N-telopeptide, urine calcium/creatinine ratio, and serum intact parathyroid hormone level. This case suggests that oral clodronate may be an effective treatment for subcutaneous fat necrosis with hypercalcemia in newborns.

並列關鍵字

Case report ； Clodronic acid ； Fat necrosis ； Hypercalcemia ； Infant ； newborn

國際替代計量

全文下載

主題瀏覽